The collapse followed Novo's downward revision of its 2025 outlook, citing weaker-than-expected international uptake of Wegovy and intensifying competition for Ozempic in the U.S. GLP-1 diabetes market. Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), behind the weight-loss drug Wegovy and diabetes medication Ozempic, tumbled on Tuesday after the company slashed its full-year 2025 guidance, triggering a sharp sell-off from investors. The stock, which closed Monday at $69, plunged to$54.37 in ...